Product Description
Casirivimab and imdevimab are monoclonal antibodies that are specifically directed against the spike protein of SARS-CoV-2, designed to block the virus attachment and entry into human cells.
Mechanisms of Action: Unknown
Novel Mechanism: No
Modality: Antibody
Route of Administration: Intravenous,Subcutaneous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: Australia | Austria | Belgium | Canada | Croatia | Czech | Estonia | European Medicines Agency | Finland | Germany | Greece | Hong Kong | Hungary | Iceland | Ireland | Italy | Japan | Latvia | Lithuania | Malaysia | Netherlands | New Zealand | Norway | Philippines | Poland | Portugal | Romania | Serbia | Slovakia | Slovenia | Spain | Sweden | Switzerland | United Arab Emirates | United Kingdom
Approved Indications: None
Known Adverse Events: None
Company: Regeneron
Company Location: TARRYTOWN NY 10591
Company CEO: Leonard S. Schleifer
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: Ghana, India, Indonesia, Nepal, South Africa, United Kingdom, United States, Vietnam
Active Clinical Trial Count: 3
Highest Development Phases
Phase 3: COVID-19|Severe Acute Respiratory Syndrome
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| RECOVERY | P3 |
Recruiting |
COVID-19|Severe Acute Respiratory Syndrome |
2026-06-30 |
|
| R10933-10987-COV-2121 | P2 |
Recruiting |
COVID-19 |
2022-11-17 |
25% |
| R10933-10987-COV-2121 | P2 |
Recruiting |
COVID-19 |
2022-11-17 |
25% |
| 2021-004535-84 | P1 |
Active, not recruiting |
COVID-19 |
2019-02-27 |